Bristol Myers Squibb has the first positive phase 3 results under its belt for mezigdomide, a second experimental drug in its much-trumpeted celmod development programme for multiple myeloma. Interim ...

Bristol Myers Squibb could be months away from bringing the first 'celmod' to market in the US, after the FDA kicked off a review of the company's iberdomide for relapsed or refractory multiple ...

The future of electric vehicles depends on battery packs that are safe, efficient, and easy to maintain. Wireless battery-management systems introduce a new way to cover all of these needs. What’s the ...

On the heels of the launch of an online direct-to-patient (DTP) program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP ...

More than 40 years after establishing the first U.S. pharmaceutical joint venture in China, Bristol Myers Squibb is handing over its controlling stake in the business. BMS has inked an agreement to ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...

Details on a BMS based on electrochemical impedance spectroscopy (EIS). BMS advances to keep pace with EV rising complexity. Building better battery models based on EIS characterization. The ...

Battery management system (BMS) hardware and software continue to evolve as electric vehicles (EVs) transition to 800-V Li-ion battery systems comprising around 200 individual cells connected in ...

BMS Group, the independent specialist insurance and reinsurance broker with an operation in Bermuda, has agreed to acquire David Roberts & Partners, the British-based independent insurance broker.

Bristol Myers Squibb is axing another big bet from the Caforio era, terminating a deal for Agenus’ TIGIT bispecific antibody three years after paying $200 million to buy into the program. Agenus ...

Bristol Myers Squibb has had a whiplash change of heart on its BCMA bispecific T-cell engager, halting (PDF) further development months after filing to run a phase 3 trial. The Big Pharma disclosed ...

QuickBMS Tutorial Please note: this tutorial uses components which have been introduced in Vortex 1.4.X; previous Vortex versions are using the deprecated event based ...